Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice

被引:17
作者
Kamberi, P
Atsuro, H
Takayoshi, T
Masaru, N
机构
[1] Oita Med Univ, Dept Internal Med 2, Oita 87955, Japan
[2] Nagasaki Univ, Sch Med, Nagasaki 852, Japan
关键词
antifungal agents; combination therapy; disseminated trichosporonosis; immunosuppressed mice;
D O I
10.1159/000007091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The activities of amphotericin B, miconazole, fluconazole, and itraconazole against Trichosporon beigelii were assessed in a mouse model of disseminated infection. Cyclophosphamide plus prednisolone-immunosuppressed ICR mice, intravenously challenged with a lethal inoculum of (6 x 10(6) CFU/mouse), were assigned to receive 7 days of therapy with amphotericin B (0.5 or 2 mg/kg/day), miconazole (10 or 40 mg/kg/day), fluconazole (10 or 40 mg/kg/day), or itraconazole (10 and 40 mg/kg/day). The efficacy of a combination of amphotericin B (1 mg/kg/day) with fluconazole (10 mg/kg/day) or itraconazole (20 mg/kg/day) with that of each agent alone was also compared. Both amphotericin B and azoles improved survival and reduced the fungal counts in kidneys of infected mice in a dose-dependent pattern. In general, fluconazole was superior to amphotericin B and the other azoles, whereas the latter two drugs were as effective as amphotericin B. The activity of amphotericin B combined with fluconazole appeared to be superior to that of each agent alone, especially in reducing the organ fungal burden. The other combination (amphotericin B plus itraconazole) had a weaker effect, but no antagonism was observed. In conclusion, azoles may be an alternative to amphotericin B for the treatment of T. beigelii infection. Furthermore, their combination with amphotericin B may improve the poor outcome seen in profoundly neutropenic patients with disseminated trichosporonosis.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 30 条
[11]  
2-Y
[12]  
*NAT COMM CONTR LA, 1992, M271 NCCLS, V12
[14]   A CONTROLLED TRIAL OF FLUCONAZOLE OR AMPHOTERICIN-B TO PREVENT RELAPSE OF CRYPTOCOCCAL MENINGITIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
POWDERLY, WG ;
SAAG, MS ;
CLOUD, GA ;
ROBINSON, P ;
MEYER, RD ;
JACOBSON, JM ;
GRAYBILL, JR ;
SUGAR, AM ;
MCAULIFFE, VJ ;
FOLLANSBEE, SE ;
TUAZON, CU ;
STERN, JJ ;
FEINBERG, J ;
HAFNER, R ;
DISMUKES, WE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (12) :793-798
[15]   THE EFFECT OF KETOCONAZOLE ON AMPHOTERICIN-B IN A MODEL OF DISSEMINATED ASPERGILLOSIS [J].
SCHAFFNER, A ;
FRICK, PG .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (05) :902-910
[16]  
SCHMITT HJ, 1991, MYCOSES, V34, P281, DOI 10.1111/j.1439-0507.1991.tb00660.x
[17]  
SHARKEYMATHIS PK, 1993, J ACQ IMMUN DEF SYND, V6, P809
[18]   COMBINATION THERAPY OF MURINE INVASIVE CANDIDIASIS WITH FLUCONAZOLE AND AMPHOTERICIN-B [J].
SUGAR, AM ;
HITCHCOCK, CA ;
TROKE, PF ;
PICARD, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (03) :598-601
[19]   INTERACTIONS OF AMPHOTERICIN-B AND SCH-39304 IN THE TREATMENT OF EXPERIMENTAL MURINE CANDIDIASIS - LACK OF ANTAGONISM OF A POLYENE-AZOLE COMBINATION [J].
SUGAR, AM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (08) :1669-1671
[20]   DISSEMINATED TRICHOSPORON-BEIGELII INFECTION IN PATIENTS WITH MALIGNANT DISEASES - IMMUNOHISTOCHEMICAL STUDY AND REVIEW [J].
TASHIRO, T ;
NAGAI, H ;
KAMBERI, P ;
GOTO, Y ;
KIKUCHI, H ;
NASU, M ;
AKIZUKI, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (03) :218-224